Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
This open label, single country trial will test if local injection of low-dose ipilimumab and nivolumab, is safe and reduces the sentinel node positivity in high-risk stage II melanoma patients.
Melanoma
DRUG: Ipilimumab|DRUG: Nivolumab|DRUG: Nivolumab
Feasibility of application of studytreatment, Feasibility as measured by the adherence to the timelines in the study protocol. A treatment arm will be declared as not feasible if 3/11 or 6/24 patients cannot adhere to the planned time of surgery due to treatment-related adverse events., Up to 100 days after treatment|Rate of effectiveness of the studytreatment, Pathological response as assessed by blinded central review, adapted from the INMC criteria, including pCR, near-pCR, or pPR (0-50% residual viable tumor in resection material), or sentinel node negativity for melanoma., Up to 5 years after randomization
treatment-related adverse events, Frequency and duration of all grade and grade 3-5, treatment-related adverse events according to CTCAE 5.0;., Up to 5 years after randomization|EFS, defined as time from start of treatment to melanoma progression (irresectable stage II or III, or stage IV disease), melanoma recurrence, treatment-related death, or melanoma-related death, whichever occurs first;, Up to 5 years after start of treatment|DMFS, defined as time between date of surgery (re-excision and SN-procedure) and date of first distant metastasis, treatment-related death or melanoma-related death, whichever occurs first;, Up to 5 years after randomization|OS, defined as time between date of start of treatment and date of death;, Up to 5 years after start of treatment
This open label, single country trial will test if local injection of low-dose ipilimumab and nivolumab, is safe and reduces the sentinel node positivity in high-risk stage II melanoma patients.